Glenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a ...

Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...

The shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...

Glenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...

Markets declined on weekly expiry day, with several companies in focus due to earnings and news. TCS reported a 6% profit increase, while I...

Glenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...

American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...

According to Bloomberg Intelligence, analysts expect a whopping 23.2% increase in earnings per share among S&P 500 companies, up from 22.3%...

Sharing details, Kamboj said the the Mumbai-based company is currently working on developing various products, including two major ones to ...

Last year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.

The drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...

Abbott has its existing innovation and development centres in Chile and Columbia for the regional needs in Latin America and one in Russia.